Penumbra now trades on a deal clock
- The main story is no longer a normal growth stock story. It is whether Boston Scientific closes the Penumbra deal.
- Q1 2026 revenue rose 15.6% year over year, so the base business still looks steady during the waiting period.
- The agreed price is $374 per share, backed by a Boston Scientific deal valued at about $14.5 billion in enterprise value.
- Thrombectomy is the largest product group, at 67.5% of 2025 revenue, and remains the main growth engine.
- The biggest downside is deal failure, which could pull the stock away from its deal-supported price and force Penumbra to sell a standalone story again.
A merger story first
Penumbra is performing well enough while it waits for Boston Scientific. In Q1 2026, revenue grew 15.6% from the prior year to $374.8 million. That growth came from existing thrombectomy products and new and existing embolization and access products.
Still, the stock is mostly tied to the merger. Boston Scientific agreed to buy Penumbra at $374 per share in a deal with an enterprise value of about $14.5 billion. The bull case is simple: the deal closes by the end of 2026 and shareholders get paid the agreed mix of cash and Boston Scientific stock.
The bear case is also simple. If regulators, closing conditions, or another surprise stop the deal, PEN could fall sharply from a price supported by the takeover. Penumbra would then need to prove it can keep growing alone after months of merger uncertainty.
Two recent facts help, but do not remove the risk. Penumbra shareholders approved the merger in May 2026, and Thunderbolt received FDA clearance in June 2026. Regulatory approval for the deal is still the key watch item.
Devices sold into hospitals
Penumbra designs, makes, and sells medical devices used by specialist doctors. Hospitals and other care providers buy the devices for procedures that remove clots, block blood flow to problem areas, or help doctors reach small vessels.
The model depends on training, sales focus, and steady product upgrades. In 2025, Penumbra added a separate U.S. sales team for peripheral embolization so that reps could focus more clearly on both embolization and the larger thrombectomy business.
This is a good business when new products win doctor trust and expand procedure use. It can break if approvals slow, hospitals delay adoption, competitors take share, or deal uncertainty causes sales people, doctors, or customers to pull back.
Clot tools at the center
INDIGO System
INDIGO is used in peripheral thrombectomy, which means removing clots outside the brain. Lightning, Bolt, and CAT RX are key systems in this line.
Penumbra System
This neuro thrombectomy line is used for clot removal in the brain. RED, JET, and ACE are key products in the system.
Lightning Bolt 12 and 6X
These products expand Penumbra into smaller arteries and smaller venous anatomy. New versions with TraX were launched in 2025 to help remove clots faster in smaller vessels.
RUBY and SMART COIL systems
These embolization products help doctors block blood flow in targeted vessels. The new dedicated U.S. embolization sales force is meant to give this group more focus.
Access catheters
Neuron and BENCHMARK help doctors reach difficult areas of the body during procedures. These tools support both neuro and peripheral work.
Thunderbolt
Thunderbolt is a computer-assisted vacuum thrombectomy device. FDA clearance in June 2026 improves its commercial chance, though the merger remains the larger stock driver.
REAL Immersive System
This Immersive Healthcare product line was discontinued in Q3 2024. It remains a reminder that Penumbra has not always allocated capital well.
Two product groups
The mix uses full-year 2025 revenue. Thrombectomy made up 67.5% of revenue, while Embolization and Access made up 32.5%; the United States also represented 77.8% of revenue, so the business is heavily U.S.-weighted.
What could break
Merger does not close
High impact · Medium oddsThis is the main risk. If the Boston Scientific deal fails, PEN could trade far below the deal-supported price. Penumbra would also need to rebuild a standalone growth case after customers and employees spent months planning around a sale.
Regulatory delay
High impact · Medium oddsThe deal still needs regulatory clearance. Even a delay can matter because it extends uncertainty for sales teams, hospitals, suppliers, and employees. Penumbra itself warned that merger uncertainty may hurt customers, employees, suppliers, vendors, and partners.
Deal uncertainty hurts operations
Medium impact · Medium oddsQ1 2026 sales were still healthy, but the waiting period is not risk-free. SG&A rose partly because of $9.4 million in acquisition-related expenses. More important, key sales people or customers could become distracted before the deal closes.
U.S. concentration
Medium impact · Medium oddsThe United States produced 77.8% of 2025 revenue. That helps when U.S. thrombectomy demand is strong, but it also raises exposure to U.S. hospital budgets, reimbursement, and competition. International revenue grew in 2025, but the U.S. became a larger share of the business.
Product cycle risk
Medium impact · Medium oddsPenumbra has long relied on new devices and upgrades to drive growth. If products like Lightning, Bolt, coils, or Thunderbolt do not gain doctor use as expected, growth could slow. Competitors in medical devices can also copy features or pressure prices.
In one breath
Is Penumbra still an independent company?
Yes, as of this page date, Penumbra is still trading while the Boston Scientific acquisition is pending. The deal is expected to close by the end of 2026 if all closing conditions are met.
What does Penumbra make?
Penumbra makes medical devices used mostly to remove clots or block blood flow in targeted vessels. Its two reporting groups are Thrombectomy and Embolization and Access.
Why does the stock depend so much on Boston Scientific?
Boston Scientific agreed to buy Penumbra for $374 per share. That deal price now anchors the bull case, while the main bear case is that the deal fails or gets delayed.
What was the latest business update?
Q1 2026 revenue rose 15.6% year over year to $374.8 million. Operating income was slightly lower year over year, partly because Penumbra had $9.4 million of acquisition-related expenses.